MAP3K19 inhibitors (Axikin Pharmaceuticals)

N/A

Report date: 2025/03/20 16:09:30
NME

Base Information

Drug NameMAP3K19 inhibitors (Axikin Pharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSPS1/STE20-related protein kinase YSK4 inhibitors
TargetsSPS1/STE20-related protein kinase YSK4
Therapy Area/IndicationsLung Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAxikin Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAxikin Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsLung Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A